This study looked at heart patients who got newer drug‑coated stents and found that a condition called tissue protrusion (TP) showed up in about half of them. While TP didn’t change the need for repeat procedures within a year, it was linked to a higher chance of another heart event after that year. The research doesn’t involve the peptide selank, so it isn’t useful for biohackers or anyone looking for peptide‑related health hacks.

Although stent implantation may be associated with tissue protrusion (TP), especially in patients with acute coronary syndrome (ACS), its long-term clinical outcomes remain unknown. The aim of the current study was to evaluate the long-term clinical outcomes of ACS patients with TP after the implantation of newer-generation drug-eluting stents (DESs). We retrospectively evaluated 366 consecutive ACS patients who underwent primary percutaneous coronary intervention (PCI) with newer-generation DESs. All culprit lesions underwent pre- and post-PCI intravascular ultrasound (IVUS) examinations and were classified according to the presence or absence of post-stent TP. After primary PCI, 198 lesions (54.1%) displayed TP on IVUS examination. At the 12-month follow-up, the incidence of target lesion revascularization did not differ between patients with (n = 198) and without (n = 168) TP (3.5 vs. 4.2%, p = 0.790). The incidence of recurrent ACS (r-ACS) was higher in patients with versus those without TP (7.1 vs. 2.4%; log-rank test p = 0.043). Cox proportional hazard analysis showed that triple-vessel disease (HR = 9.258, p = 0.001), TP (HR = 3.149, p = 0.008), and low-density lipoprotein cholesterol reduction rate ≥ 50% (HR = 0.184, p = 0.008) were the independent predictors of r-ACS. TP detected using IVUS after DES implantation may be associated with the occurrence of r-ACS after the 12-month follow-up, although short-term clinical outcomes were not worse during the 12-month follow-up.